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Abstract
Underlying injures produced by Hemolytic Uremic Syndrome, a clinical entity defined by the triad, inclu-
de:  non-immune hemolytic anemia, thrombocytopenia, and organ involvement which are measured by the 
Trombotic Systemic Microangiopathy (TSM)  process. The atypical HUS (HUSa) is a subtype of HUS in 
which the phenomena of TSM are the result of the lack of regulation in alternative pathway of complements 
on cell surfaces, secondary to a genetic cause. The key role played by the deregulation of the complement 
system on the damaged endothelial layer in patients with HUSa has been established;   this system measures 
by multiple mutations and polymorphisms in the genes that encode certain regulatory proteins of the add-in 
has been established. Taking into account the great complement activity of physiological way during ges-
tation, each day more cases of HUSa related to pregnancy, are described.  There is a monoclonal antibody, 
Eculizumab, which inhibits the terminal complement fraction (C5). Eculizumab blocks the formation of the 
attack complex of the membrane, with significant long-term improvement in morbidity and mortality asso-
ciated with this disease, promoting long-term recovery of renal function and with a significant reduction in 
the need for dialysis or plasma therapy.
A case of 17 year in puerperium, who developed icteric syndrome considered as HELLP syndrome, whose 
atypical evolution made us think about alternative diagnosis of thrombotic microangiopathy in pregnant 
woman HUSa type. Discard diagnosis between sepsis, HELLP syndrome and disseminated intravascular 
coagulation was made.  ADAMST13 measurement was taken, whose standard value allowed us to make 
the differential diagnosis with a Thrombotic Thrombocytopenic Purpura (TTP). In this way, we were able to 
achieve the clinical diagnosis of HUSa and begin treatment.
Key words: Hemolytic Uremic Syndrome atypical, Eculizumab, thrombotic microangiopathy, pregnancy. 
(MeSHsource).
Microangiopatías trombóticas en la UCI, síndrome hemolítico urémico atípico 
posparto: reporte de caso y revisión de la literatura
Resumen
El síndrome hemolítico urémico es una entidad clínica definida por la tríada: anemia hemolítica no inmune, 
trombocitopenia y compromiso de órgano, en la que las lesiones subyacentes están mediadas por un proceso 
de Microangiopatía Trombótica (MAT) sistémica. El SHU atípico (SHUa) es un subtipo de SHU en el que 
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los fenómenos de MAT son consecuencia de la pérdida de regulación de la vía alternativa del complemento 
sobre las superficies celulares, secundario a una causa genética. Se ha establecido el papel clave que desem-
peña la desregulación del sistema de complemento en la inducción de daño endotelial en los pacientes con 
SHUa, esto mediado por múltiples mutaciones y polimorfismos en los genes que codifican determinadas 
proteínas reguladoras del complemento. Cada día se describen más casos de SHUa relacionados al embarazo, 
teniendo en cuenta la gran actividad del complemento de manera fisiológica durante el estado de gestación. 
Eculizumab es un anticuerpo monoclonal que inhibe la fracción terminal del complemento (C5), bloqueando 
la formación del complejo de ataque de membrana, con mejoría significativa de la morbimortalidad asociada 
a esta enfermedad, logrando recuperación de la función renal a largo plazo y con una reducción importante 
en la necesidad de diálisis o terapia plasmática.
Se presenta un caso de una mujer de 17 años de edad en puerperio inmediato, quien presentó síndrome 
ictérico considerado como síndrome de HELLP, cuya evolución atípica hizo pensar en diagnóstico alterna-
tivo de Microangiopatía Trombótica en mujer embarazada tipo SHUa. Se realizó diagnóstico de descarte 
entre sepsis, HELLP y coagulación intravascular diseminada. Se hizo medición de ADAMST13, cuyo valor 
normal permitió hacer el diagnóstico diferencial con una Púrpura Trombocitopénica Trombótica (PTT). De 
esta manera, se logró realizar el diagnóstico clínico de SHUa e iniciar tratamiento dirigido con excelente 
respuesta clínica.
Palabras clave: Síndrome hemolítico urémico atípico, eculizumab, microangiopatía trombótica, embarazo 
(fuente DeCS).
Introduction 
Much progress has been achieved in the understanding of the pathophysiology of HUSa since the initial description of two 
main categories of Hemolytic Uremic Syndrome. It 
is recognized as a genetic disease that is life threa-
tening, characterized by the uncontrolled activation 
of the complement system, and its conditions the 
appearance of thrombotic microangiopathy by sys-
temic (TMA) and severe damage of target organ.
The first case, based on two main categories of 
systemic Trombotic microangiopathy (TMA) and 
thrombotic thrombocytopenic purpura (TTP), was 
described in 1924 by Moschcowitz 17, and was ca-
lled Hemolytic Uremic Syndrome(HUS)by Gasse-
ren in 1955. 18Since then, there has been no more 
than a handful of critical advances in the diagnosis 
and treatment of TMA; however, each one of these 
discoveries has geometrically altered the course of 
HUSa.
The recognition of the plasma exchange therapy 
(PET) as the treatment of choice for the TTP; the 
isolation of E. coli producer of shiga toxin STEC as 
the etiologic agent of many cases of HUS associa-
ted with diarrhea, now known as HUS STEC; and, 
recently, the description of the activity in a speci-
fic protease (ADAMTS13) as the correct diagnostic 
method of the PTT, has allowed to improve the diag-
nostic and therapeutic possibilities of these patients. 
However, great advances  in the description of the 
fundamental role of the complement system in the 
pathophysiology of HUSa, has made it possible to 
expand the knowledge and the possibilities of treat-
ment directed to the latter entity in the last decade. 
This paper focuses on HUSa as a life threatening, 
rare systemic and chronic disease, with a very high 
degree of mortality and morbidity within the first 
year of diagnosis, unless be treated appropriately.
Normally there are two ways to define HUS. The 
most frequently used definition, which is presented 
in the90 per cent of the cases, is HUS typical or clas-
sical and it  is associated with diarrhea caused by the 
infection of E.coli, which is produced by Shiga toxin 
STEC. STEC is able to join the Gb3 receivers on the 
surfaces of the endothelial cells and cause their des-
truction, either directly or through the activation of 
the inflammatory and procoagulant cells. Most pa-
tients with SHU STEC evolve satisfactorily within 2 
to 3 weeks while 10% of the cases may evolve into 
chronic kidney disease, only 25% of these develop 
permanent renal sequels. Ten per cent of the remai-
ning cases present as SHUa, multisystemic disease 
measured by the deregulation of the complement 
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system and a  worse prognosis, because 40% of the 
patients die or they are on dialysis with the first ma-
nifestation and 63 per cent of the survivors progress 
to Terminal Chronic Renal Disease (CRD) or die in 
the course of the first year after diagnosis. The HUSa 
has an incidence of approximately 2 cases per mi-
llion inhabitants/year and a reported prevalence of 4 
to 6 per million inhabitants.
In the following I will describe the first case of HUSa 
related to pregnancy published in Colombia. 
Clinical Case
17 years old female patient,  without prior history, 
previously healthy, in immediate postoperative pe-
riod of a cesarean section by diagnostic suspicion 
of HELLP syndrome. The patient characterized by 
three days - progressive jaundice condition, 36 wee-
ks, of pregnancy without prenatal controls, previous 
physical examination after she was admitted then 
she was transferred to the Intensive Care Unit (ICU): 
the alertness of the patient, she was conscious with 
vital signs of TA: 123/93mmhg, FR: 18, FC:105, 
SCG: 15/15, SAT: 98% to air, jaundice of the skin 
and mucous generalized, rhythmic heart sounds ta-
chycardia rhythms, breath sounds without additions, 
soft and palpable abdomen,  below umbilical, surgi-
cal wound without bleeding, grade 1 edema of the 
lower limbs, hyperreflexia universal. Paraclinical 
data after admission: 15,900 leukocytes, Hb: 15, PT: 
14 (13),PTT:30 (23), platelets: 88000, total biliru-
bin level was 12.5, direct bilirubin level was10.8, 
indirect bilirubin level was 1.7,GPT: 44, GOT:10, 
creatinine level :2.3, BUN:27, LDH: 1143U/L, chest 
radiography with slight redistribution of fluids.
A pregnant patient with HELLP syndrome was con-
sidered, with icteric syndrome, bilirubin level was 
11 , that is why cholestasis and/or choledocholithias 
is has been discarded  to be carried out through he-
pato-billiary echographies,  reported as normal, at 
the same time, the cholangio-resonance, looks for 
extra liver duct obstruction. Multiple samples to 
search for infectious processes with a suspected in-
tra-abdominal and treatment with cefepime and me-
tronidazole antibiotics start.
Patient evolves so torpid with systemic deterioration 
and, on the second day, she persisted with multiple 
organ dysfunction (renal, hepatic, hematological) 
coagulopathy with thrombocytopenia and consump-
tion of fibrinogen, evidence of hydric overload in 
chest x-ray, HTA with intravenous nitroglycerin 
treatment and requirement of non-invasive mecha-
nical ventilation. Likewise, she requires odilator 
with dobutamine treatment. Patient persists with 
torpid evolution, signs of systemic inflammatory 
response without infection focus on persistence of 
metabolic acidosis, despite the revival and support 
inodilator, and good urine output. The third day, the 
patient becomes oligo-anuric with irregular respon-
se to medical treatment, so that she is evaluated by 
nephrology unit, which initiates infusion of  2 mg 
/ hour furosemide . It was observed that HB fell to 
8 without evidence of bleeding. The fourth day, the 
patient shows partial improvement of hemodyna-
mic, best rates of perfusion and urine output; howe-
ver, neurologically compromised given the delirious 
condition associated with cardiorespiratory failure, 
which requires initiation of conventional mechani-
cal ventilation was evident. Paraclinical control: Hb: 
10.1, Leukocytosis: 18500, platelets: 56000,Creati-
nine: 3, BUN: 65, TGO: 51.6, TGP: 23.1,  increased 
uric acid, the ultrasound test shows a wall hematoma 
with hemo-peritoneum so she is taken to surgery for 
an exploratory laparotomy finding liquid sero-asci-
tic and wall hematoma, which does not explain the 
acute anemia evident in the patient.
The fifth day, the patient evolves with progressi-
ve clinical deterioration, with acute renal failure 
established with HB at 8 with multiple organ dys-
function that evolves dependent on pressure vessel 
support, without showing site of infection, kidney 
failure with nitrogenous increased (creatinine 3.4, 
BUN:76) and volume overload. Prolonged coagula-
tion times, lipemic serum and it is decided to per-
form staging to meropenem on suspicion of sepsis. 
High transfusion requirements (6 UGRE, 24 U pla-
telets and 8U of plasma). Taking into account the se-
verity of the disease and non-clinical evolution and 
improvement, five days after finishing pregnancy, 
HELLP syndrome is considered differential possi-
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ble diagnoses and, because there is no presence of 
infectious agents, it is physicians consider to study 
possible  and different causes of TMA. Haptoglo-
bin is recommended ADAMTS13, complement 
tests  and spread of peripheral blood and take other 
para-clinical tests in order to complete studies and 
the results were: Profile of autoimmunity:  negative, 
HIV negative, direct and indirect Coombs: negative, 
Leptospira: negative. 
The sixth day, multiple organ dysfunction with seve-
re compromises to renal activity, oligúric, metabolic 
acidosis and  water load continues. Coagulopathy is 
controlled, but persists with clear signs of intravas-
cular hemolysis, given by LDH in persistent increa-
se despite the medical management established and 
thrombocytopenia in progression. A TAC scan of 
the chest (Figure 1),finds bilateral pleural effusion 
and the presence of severe ascites. Upper endoscopy 
performed has not demonstrated digestive bleeding 
despite persistent anemia. Para-clinical control: Pla-
telets: 67000mm, creatinine: 2.5, BUN: 96,TGO: 
103,TGP: 33,BT: 12,triglycerides: 1354, HB: 8.
The patient is still with evident anemia, THROM-
BOCYTOPENIC, with increased renal failure, 
hyper-bilirubinemia and elevated liver enzymes wi-
thout finding infectious agent or bleeding and with 
neurological affection given by delirium. Negative 
cultures, without achieving clinical response despite 
being more than a week under medical management, 
which is not common in preeclampsia, HELLP, and 
makes preponderant consider HUA as her postpar-
tum diagnostic .
By the twelfth day, the patient continues with MAT 
active and severe neurological involvement, en-
cephalopathy and presenting, in addition, episode 
of seizure by what is done CT of the skull (Figure 
2), evidencing: ischemic zone left temporal. Again 
it is evaluated by the gynecology department, which 
performs medical board discarding infectious pro-
cesses related and continues to expectant treat-
ment in ICU. Paraclinial additional for differential 
approaches of systemic MAT with activity report of 
ADAMTS13:64%;complement test : C3: 73.4mg/
dl (90-180mg/dl);C4: 8.6 mg/dl (10-40 mg/dl),bo-
Figure 1
A CT scan of the chest with bilateral pleural effusion
Source: Zulma Urbina, Rayza Soledad
Figure 2
Simple brain CT. Ischaemic zone left temporal
Source: Zulma Urbina, Rayza Soledad
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th diminished, without evidence of concomitant au-
toimmune disease. It is MAT status associated with 
pregnancy, with torpid evolution despite treatment 
of HELLP syndrome as a first diagnostic approxi-
mation, with a result of ADAMTS13 that discards 
the presence of PTT associated with pregnancy and 
it is considered HUSaas definitive diagnosis, which 
explains the persistence of severe systemic commit-
ment, MAT persistent, the HTA of difficult mana-
gement that requires polypharmacy and the  current 
multisystem involvement, by which it decided to 
launch plasmapheresis, pending availability of treat-
ment directed to lock the snap-in. Sorts previous 
vaccination against meningococcus was applied . 
The patient continues encephalitic, convulsive sta-
tus, managed with valproic acid, sedation with ben-
zodiazepines and propofol, spontaneous bleeding by 
tracheal tube.
The thirteenth day hematology dpt. decides to start 
Eculizumab because of HUSa. The following day, 
hemodynamic response it is observed, diminishing 
the TMA and extubation of the patient on a program-
med manner. RMN control is performed (Figure 3) 
of control. It continues Eculizumab infusion accor-
ding to the weekly schedule. After three weeks of 
handling treatment by blocking the complement, the 
patient improved very appropriately in relation with 
tensional figures, liver dysfunction and normaliza-
tion of the renal function.
Discussion
HUSa is a chronic genetic pathology, that threatens 
the life, where deregulation of the complement alter-
nate routing causes multisystem involvement. Diffe-
rent entities amplify the complement system, either 
physiological, such as pregnancy, or pathologic, such 
as infections, surgeries among others, exposes the 
underlying HUSa have been described. As previous-
ly mentioned in this paper, the HUSa makes part of 
the systemic TMA where the diagnosis is made in a 
clinical way, back to rule out other causes of TMA 
(which are mentioned below). In this opportunity, 
we describe a case of HUSa related to pregnancy. 
Figure 3
MRI of the brain. Ischemic zone left temporal, shows cerebral infarction small temporary corti-
cal later left + + focal HSA discreet perilesional edema
Source: Zulma Urbina, Rayza Soledad
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HUSa  is caused byTMA during the third trimester 
of pregnancy or in the postpartum period. Pregnancy 
is associated with a systemic activation of the com-
plement system to protect both the mother and the 
fetus from possible infections.  It has been shown 
that the levels of the anaphylatoxins C3a, C4a and 
C5a are higher in pregnant women than in non-preg-
nant, around three times more1. Among every 100 
cases of women with HUSa, 21 per cent were related 
to pregnancy2. HUSa  related to pregnancy has been 
reported in the international register SHUa/PTT and 
are abnormalities of the complement system in 86% 
of these patients3. The case reported in this paper is 
considered to be the first one published in Colombia.
Pathogenesis
The complement system is responsible for the de-
fense against microorganisms; its objective is the 
lysis of these microorganisms through the activa-
tion of three tracks: the classical pathway, the lec-
tin pathway and the alternative pathway. Clarifying 
that the disorder is in the regulation of one of these 
three routes, of the alternative pathway, which con-
duct to HUA the clinical manifestations, it should be 
observed that this track is active continuously with 
the spontaneous activation of C3 and it is amplified 
quickly thanks to the action of proteins such as en-
dotoxins and immunoglobulins, among other.LaC3 
convertase is formed by C3B/BB; C3b covers cell 
surfaces and works as an opsoninon the walls of the 
microorganisms. When you join the C3 convertase, 
to create the C5 convertase, this cleaved or divided 
aC5 in c5a and C5b, releasing C3a and C5a that are 
chemo-tactical of leukocytes and platelets, which 
activate the path of coagulation and participate in 
the endothelial activation, C5a being highly proin-
flammatory. 
All this mechanism is controlled by inhibitory pro-
teins or regulatory mechanisms as are the Factor I 
(IFC), the factor H (FCF), the protein of the cofac-
tor of the Membrane (PCM), the Trombomodulina 
(THBD), the Factor of accelerating deterioration 
(DAF/CD55), Protectina or CD59, responsible for 
stopping the immune response, thus avoiding dama-
ge to own guest4.
Patients with HUSa lack, intrinsically, the regulators 
of the complement system, allowing an overactive 
response; inducing endothelial damage and micro-
vascular thrombosis secondary to inflammation and 
a continuous activation of the complements, which 
allows different clinical manifestations and compli-
cations and high morbimortality.
The term MAT (thrombotic microangiopathy) means 
histologic damage of the arterioles and capillaries, 
characterized by thickening and inflammation of the 
vessel wall, detachment of endothelial cells; the su-
bendothelial elongation, caused by the deposits of 
protein and the material of the cellular lysis; and the 
presence of platelet thrombi that occlude the vascu-
lar spaces, which can be suspected by the decrease 
in the platelet count, hemolysis, and even of syste-
mic form with multiple injuries to different bodies4.
There are two clinical entities concerned on inju-
ries of primary thrombotic microangiopathy, which 
both differ in its physipathologic basic cause: the 
thrombotic thrombocytopenic purpura(PTT) and the 
SHU6.
90%of cases of SHU are caused by an enteric in-
fection by STEC, derived from contaminated food 
(SHU typical/STEC)7. In the U.S., it is estimated 
that HUSa has an annual incidence rate of 1-2 cases 
per million inhabitants5and, in Europe, a Multicen-
ter international study reported an incidence of 0.11 
cases per million inhabitants between the ages of 0 
and 18 years old 6,9. The distribution men: women 
is equitable in childhood, but tended to predominate 
in women in adult life. The clinical manifestations 
can be multiple and varied in each patient. The com-
pletion of a relevant interview and physical exam 
will allow for a complete medical history. Genera-
lly SHU manifests as an abrupt start9, but in 20% 
of patients manifestation can be progressive with 
subclinical anemia, thrombocytopenia fluctuating 
and renal function preservation. The table is charac-
terized by the triad of microangiopathichaemolytic 
anemia not immune, thrombocytopenia—or 25% 
consumption –and commitment of organ, such as the 
acute renal failure10. High levels of lactic dehydro-
genase, the undetectable levels of haptoglobin and/
or the presence of esquistocitos confirms the exis-
tence of intravascular hemolysis11.The presence of 
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HTA because of volume overload or vascular lesion 
is frequent, like the oligoanuria in the acute renal 
failure. HUSa  injury predominantly affects the renal 
vessels; the diffuse nature of the TMA leads to the 
affectation of the microvasculature of organs (brain, 
heart, intestines, pancreas and lungs), which exp-
lains the emergence of the extrarenal9,12 sign-symp-
tomatology. The most frequent are the neurological 
(48%), including irritability, drowsiness, confusion, 
seizures, encephalopathy, stroke, hemiparesis, or a 
hemiplegia coma12-14, as happened with this patient. 
The acute myocardial infarction has been reported 
in up to 3 per cent of the patients with HUSa, being 
able to relate with sudden death12,15.The variability 
of the symptomatology hinders the differential diag-
nosis with other causes of TMA.
The relationship of HUSa and pregnancy has been 
exposed previously by other authors, in the same 
way the relationship of MAT and pregnancy, repor-
ted by Fakhouri, et al.2, with an approximate inci-
dence of 1 in 25000 pregnancies. The dysfunction of 
the complement system has been related, recently, 
with pathologies such as HELLP. This increase in 
the snap-in during the state of gestation is controlled 
in normal women through regulatory proteins, like 
DAF, MCP and CD59, which are located on the cell 
surface of the trophoblast. On the contrary, in wo-
men with alterations in the regulation of the plug-in, 
as occurs in the HUSa, could explain the unmasking 
of HUSa associated with pregnancy. Further, as it 
was described by Fakhouriet al.2, after childbirth, 
which could increase, per se, the activation of the 
complement system and explain the greater number 
of cases of HUSa diagnosed after childbirth.
Diagnosis
HUSa is a pathology of clinical diagnosis. Within 
the multiple parameters studied, the most accurate 
method for the diagnosis is based on the exclusion 
of TMA, and keep in mindthe common symptoms of 
commitment of organs by the microangiopathy:la-
boratory values compatible with the presence of in-
travascular hemolysis not immunological, as is the 
elevation of the LDH secondary to fragmentation of 
red blood cells, presence of schistocytes in the ex-
tended peripheral blood, Coombs negative, hemog-
lobin values low or undetectable levels of hapto-
globin; mention must be made of the classical triad 
characterized by:1) hemolysis microangiopática, 2) 
thrombocytopenia, and 3) organ damage, with the 
greatest frequency of acute kidney injury (hematu-
ria, proteinuria or reduced kidney function). This is 
a condition that is potentially fatal and requires im-
mediate treatment to prevent the irreversible damage 
of the organs or death.
The most common causes of TMA are the thrombo-
tic thrombocytopenic purpura (TTP), the Hemolytic 
Uremic Syndrome (HUS),which in turn is divided 
into SHU STEC (caused by the Shiga toxin of E. 
coli invasive integer) and HUSa (chronic disease, 
genetics by deregulation of the complement sys-
tem). Unlike the HUS as described previously, the 
intravascular thrombosis in the TTP is the result of 
a severe deficiency of the activity of the metallo-
protease ADAMST13, a plasma enzyme in charge 
of fragmenting Von Willebrand15. factor multimers. 
Currently, a severe deficiency acquired or congenital 
of ADAMTS13 (<5-10%)confirms the diagnosis of 
thrombotic thrombocytopenic purpura (TTP). This 
blood sample should be taken before the beginning 
of the plasmapheresis or plasma infusion, not to alter 
their outcome12. On the other hand, the HUS-STEC 
is caused by the Shiga toxin produced by the Es-
cherichia coli invasive integer, which is detected by 
PCR techniques in stool or in a positive culture for 
this germ. 
The TMA can occur in other contexts, formerly re-
cognized as secondary mat by its association with 
other pathologies; however, it is worth emphasizing 
that there exist conditions amplifiers of the add-
in that can expose the diagnosis of HUSa of base. 
Among these, the most frequent are: Malignant ar-
terial hypertension, HELLP syndrome, autoimmune 
diseases (LES), HIV, pneumococcus infection, glo-
merulopathies, neoplasms and medication, among 
others. In these conditions, these events or patholo-
gies are considered the triggering factor of HUSa, 
exposing the patient to suffer all clinical manifesta-
tions of this pathology.
Recent studies have shown that 40-60 % of patients 
with HUSa are carriers of specific mutations in the 
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genes of the plug-in, causing deregulation15of the 
alternative pathway of the complement in the more 
common are Factor H(CHF) (20-30%), MCP (5-
15%), Factor I (4-10%), C3 (2-10%), factor B (1-
4%) and THBP (3-5%)12.
Given the wide variety of mutations and the incom-
plete penetration of the same, in addition to that, in 
approximately 50 per cent of the cases it is not pos-
sible to identify the mutation, genetic tests are not 
a diagnostic criterion4. In all patients with clinical 
suspicion of HUSa, it is recommended to measure 
the levels of C3 and C4 in serum, which can help to 
clarify the diagnosis without being this a fundamen-
tal factor.
Treatment
Plasmapheresis: recent evidence suggests that the 
therapy of plasma exchange / plasma infusion(PF/
IPes) is ineffective to adequately control the syste-
mic and permanent activation of the complement in 
patients with HUSa. Plasma therapy is reasonably 
effective in the normalization of the hematological 
parameters of thrombotic microangiopathy, but is 
not uniformly effective in preventing the progres-
sion of kidney disease16.
Noris and collaborators’ study12 shows that 70% of 
the patients with diagnosis of HUSa commutations 
CFH, CFI, C3 or THBD, or anti-body anti-FCF died 
Tabla 1
Dosis de Eculizumab para pacientes menores de 18 años
 
Tomada de Córdoba et al.4
 
Para pacientes menores de 18años de edad, la terapia con Ecu-
lizumab consiste en:
• 900 mg semanalmente durante las primeras 4 semanas, se-
guido de
• 1200 mg en la quinta semana y luego
• 1200 mg cada 2 semanas.
Figure 4
Graph1.algorithm for differential diagnosis of thrombotic microangiopathy document of Colombian 
consensus1.
ADAMTS13: a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; LDH: 
lactate dehydrogenase;  MAT: thrombotic microangiopathy; PTT: thrombotic thrombocytopenic purpura; 
SHU: called hemolytic uremic syndrome;
SHUa: called hemolytic uremic syndrome atypical; STEC: Shiga toxin-producing Escherichia coli. LES: 
Systemic Lupus Erythematosus. HELLP: síndrome HELLP. Tomado de Córdoba et al.4
Consider therapeutic plasmapheresis, 5 sessions using fresh frozen 
plasma as replacement fluid while it is waiting for results
Causes, to develop complement (HELLP) ADAMTS 
13 and and /or serum creatinine 17mg/d Postpartum 
Preeclampsia STEC test it is probably ADAMTS13 
(TTP) severe
without response therapeutic plasmapheresis 
Activity normal status LDH  platelet count 
and 25%  decrease in creatinine
Consider SHUa early diagnostic
test negative and / or ADAMT13test – positive STEC
ADAMTS 13 Activity
ADAMTS 13 and STEC test
If blood platelet count is 30.000 and /or serum 
creatinine 17mg/d it is probably ADAMTS13 (TTP) 
severe deficiency
neurological involvement cardiovascular involvement
gastrointestinal involvementRenal involvement  
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Table 1
Dose of Eculizumab for patients under the age of 18 years
Taken from Cordoba et al.4
or came to  end-stage renal disease during the first 
three years of the diagnosis, even in the course of 
plasmapheresis as standard operation.
Eculizumab: is a humanized monoclonal antibody 
that blocks the excision of terminal complement C5 
protein in the inflammatory protein C5a and C5b, 
preventing the generation of complex C5B-9 termi-
nal complement1. Taking into account the pathophy-
siology of the disease, in relation to the deregulation 
of the complement system, Eculizumab blocks the 
terminal complement action, preventing the injury 
and chronic damage of the body, thus protecting the 
patient from the devastating consequences of the 
hyperactivity of the complement system. Multiple 
clinical studies have demonstrated the benefits of 
this therapy to change the natural history of this de-
vastatingdisease and ultra-orphan4.
The recommended dose of Eculizumab for patients 
under the age of eighteen years of age is done ac-
cording to the body weight, taking into account the 
following table:
It is advisable to consider Eculizumab as a therapeu-
tic strategy in patients with TMA in those who do 
not observe the therapeutic response of the plasma 
exchange or there is16 dependency of this therapy. 
The inhibition of the TMA, mediated by the com-
plement with Eculizumab, led to rapid hematologic 
improvements, significant improvements in the re-
nal results and the disruption of plasma exchange/
infusion of plasma (PE/PI) and dialysis in the majo-
rity of patients, as well as in the case of this article.
According to Roxanne and collaborators15, in pa-
tients with HUSa, with and without complement 
mutations identified, the terminal complement locks 
with Eculizumab and interrupts the progression of 
inflammation to the renal injury and prevents dys-
function of the organs, despite the evidence of per-
sistent AP and the activation of endothelial cells.
Conclusion 
HUSa is an ultra-orphan disease, characterized by 
the presence of TMA, which is defined by the triad: 
non-immune hemolytic anemia, thrombocytopenia 
and compromised organ activity. In the pathophysio-
logy of HUSa, the phenomena of TMA are a result of 
the lack of regulation of the alternative pathway of 
complement on the cell surfaces, secondary to a ge-
netic cause, which led to the endothelial damage and 
multi organ involvement. Each day more pregnan-
cy related cases of HUSa  are described, taking into 
account the great physiological complement activity 
during gestation. The case reported is considered to 
be the first of its kind in our country. Eculizumab 
is a monoclonal antibody that inhibits the terminal 
complement fraction (C5), blocking the formation 
40kg and more   900 mg per week x 4 doses 1200 per week 5 ; later 1200 mg e/week
30 kg and less than 40 kg  600 mg per week x 2 doses 900 mg per week 3; later 900 mg e/2 weeks
20 kg and less than 30 kg  600 mg per week x 2 doses 600 mg per week 3; later 600 mg e/2 weeks
10 kg and less than 20 kg  600 mg per week x 1 doses 300 mg per week 2; later 300 mg e/2 weeks
5 kg and less than 20 kg  300 mg per week x doses  300 mg per week 2; later 300 mg e/2 weeks
Patient weight   Inducement      Treatment
For patients under 18 years of age, therapy with Eculizumab consists of:
• 900 mg weekly during the first 4 weeks, followed by
• 1200 mg in the fifth week and then
• 1200 mg every 2 weeks.
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of the attack complex of the cell membrane, with 
significant improvement in morbidity and mortality 
associated with this disease, allowing long term re-
covery of renal function and significant reduction in 
the need for dialysis or plasma therapy. Proper un-
derstanding and timely diagnosis of this entity and 
its relation with the pregnancy will allow these pa-
tients to be treated in a timely manner, avoiding the 
severe sequels of morbidity associated with ERC V 
and/or premature mortality.
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